Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602068 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL
A Phase 2 study, sponsored by Eyegate Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT01602068 is a Phase 2 study that has completed, run by Eyegate Pharmaceuticals. The registered enrollment target is 45 participants.
The verdict
NCT01602068, a Phase 2 study, has completed, sponsored by Eyegate Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to placebo in patients undergoing cataract surgery with implantation of a posterior chamber intraocular lens.
Interventions
- DRUG Dexamethasone Phosphate Ophthalmic
- DRUG 100 mM Sodium Citrate Buffer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01602068
The ClinicalTrials.gov registry entry for NCT01602068 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eyegate Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone Phosphate Ophthalmic is the first listed.
NCT01602068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01602068 about?
NCT01602068 is a clinical study titled "Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL". The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to placebo in patients undergoing cataract surgery with implantation of a posterior chamber int...
What is the current status of trial NCT01602068?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2012-05. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01602068?
The interventions under investigation include: Dexamethasone Phosphate Ophthalmic (DRUG), 100 mM Sodium Citrate Buffer (DRUG).
Who is sponsoring clinical trial NCT01602068?
This trial is sponsored by Eyegate Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.